Tumour lysis syndrome with hypocälcaemia in accelerated chronic granulocytic leukaemia.
Tumour lysis syndrome is a well-known complication of lymphoid malignancies, but it has rarely been described in myeloproliferative disorders. A patient is reported with myeloblastic type of accelerated chronic granulocytic leukaemia who developed a tumour lysis syndrome following intensive chemotherapy. The most prominent manifestation of such a syndrome was hypocalcaemia, which was associated with other biochemical alterations, including hyperphosphataemia, hyperuricaemia and renal failure.
D000328:Adult; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006996:Hypocalcemia / Q000097:blood*; D007951:Leukemia, Myeloid / Q000097:blood / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D013577:Syndrome; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D011241:Prednisone; D003630:Daunorubicin